Loading clinical trials...
Loading clinical trials...
A Phase I, Relative Oral Bioavailability Study of Different Fixed Dose Combinations of Dolutegravir and Lamivudine in Healthy Subjects
Conditions
Interventions
Dolutegravir 50 mg tablet
Lamivudine 300 mg tablet
+2 more
Locations
1
United States
GSK Investigational Site
Overland Park, Kansas, United States
Start Date
May 1, 2016
Primary Completion Date
June 1, 2016
Completion Date
June 1, 2016
Last Updated
January 18, 2017
NCT06719310
NCT02831673
NCT02075593
NCT01231516
NCT02178592
NCT02415595
Lead Sponsor
ViiV Healthcare
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions